APCCC 2024: High-Risk and Locally Advanced Prostate Cancer in the Context of Current Diagnostic and Therapeutic Options – Which Is the Ideal Definition to Use for Clinical Practice?
APCCC 2024, Prostate Cancer, Ten-year prostate cancer-specific survival rates, CALGB 90203 trial, androgen deprivation therapy (ADT), docetaxel, ADT plus docetaxel, PROTEUS trial, apalutamide, ADT plus apalutamide, genomic biomarker-driven therapy for prostate cancer, GUNS trial, Apalutamide plus ADT plus or minus additional genomic biomarker-driven therapy, enzalutamide.